Article
The Role of PD-L1 in Treatment Decision-Making for Perioperative EGFR-Mutated Lung Cancer and its Genomic Analysis.
Annals of surgical oncology - 1 Oct 2026
Qi Yi-Fan, Qiu Zhen-Bin, Huang Wei-Ye, Zhang Chao, Fu Rui, Jie Guang-Ling, Yang Xiong-Wen, Lin Yi-Duo, Li Hong-Ji, Cui Qian, Su Jian, Xie Zhi, Jiang Ben-Yuan, Zhang Xu-Chao, Yang Xue-Ning, Wu Yi-Long, Zhong Wen-Zhao
Abstract excerpt
BACKGROUND: Epidermal growth factor receptor-mutated (EGFR-M+) non-small-cell lung cancer (NSCLC) represents a substantial proportion of lung cancer and remains associated with a considerable risk of postoperative recurrence despite advances in targeted therapies. The role of programmed death-ligand 1 (PD-L1) expression in the perioperative treatment of EGFR-M+ NSCLC remains controversial. The gene mutation...
Read the complete abstract on PubMedTopics
- Humans
- Lung Neoplasms
- ErbB Receptors
- B7-H1 Antigen
- Mutation
- Female